Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: Characterization of a novel nucleobase transporter

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 6, 2007, Pages

  Bone, Derek B J ^a   Hammond, James R ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adenosine; Cardiovascular; Human; Hypoxanthine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADENOSINE DERIVATIVE; CHLOROADENOSINE; HYPOXANTHINE; NITROBENZYLMERCAPTOPURINE; NUCLEOBASE TRANSPORTER; NUCLEOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYPOXIA; ISCHEMIA; PRIORITY JOURNAL; VASCULARIZATION;

2-CHLOROADENOSINE; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CELLS, CULTURED; CHILD, PRESCHOOL; CORONARY VESSELS; DILAZEP; DIPYRIDAMOLE; DOGS; ENDOTHELIAL CELLS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; FEMALE; HUMANS; HYPOXANTHINE; KINETICS; MICROCIRCULATION; NUCLEOBASE TRANSPORT PROTEINS; PIPERAZINES; PROTEIN BINDING; PURINES; RATS; SWINE; THIOINOSINE; TRANSFECTION; TRITIUM;

EID: 36849010349     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01006.2007     Document Type: Article

References (29)

1. Aguayo C, Casado J, Gonzalez M, Pearson JD, Martin RS, Casanello P, Pastor-Anglada M, Sobrevia L. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta 26: 641-653, 2005.
2. Archer RG, Pitelka V, Hammond JR. Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells. Br J Pharmacol 143: 202-214, 2004.
3. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch 447: 735-743, 2004.
4. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
5. Bone DB, Robillard KR, Stolk M, Hammond JR. Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2. Mol Membr Biol 24: 294-303, 2007.
6. Boumah CE, Hogue DL, Cass CE. Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells. Biochem J 288: 987-996, 1992.
7. Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 88: 349-425, 2000.
8. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108, 1973.
9. Deussen A, Stappert M, Schafer S, Kelm M. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation 99: 2041-2047, 1999.
10. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 27: 647-654, 2005.
11. Engel K, Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68: 1397-1407, 2005.
12. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279: 50042-50049, 2004.
13. Gorlach A. Control of adenosine transport by hypoxia. Circ Res 97: 1-3, 2005.
14. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflügers Arch 447: 728-734, 2004.
15. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 18: 53-63, 2001.
16. Jarvis SM, Martin BW, Ng AS. 2-Chloroadenosine, a permeant for the nucleoside transporter. Biochem Pharmacol 34: 3237-3241, 1985.
17. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27: 416-425, 2006.
18. Lin W, Buolamwini JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogs as equilibrative nucleoside transporter 1 inhibitors. J Med Chem 50: 3906-3920, 2007.
19. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 27: 1004-1013, 2007.
20. Nemeth I, Talosi G, Papp A, Boda D. Xanthine oxidase activation in mild gestational hypertension. Hypertens Pregnancy 21: 1-11, 2002.
21. Osses N, Pearson JD, Yudilevich DL, Jarvis SM. Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine- insensitive equilibrative nucleoside transporter. Biochem J 317: 843-848, 1996.
22. Podgorska M, Kocbuch K, Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52: 749-758, 2005.
23. Redzic ZB, Gasic JM, Segal MB, Markovic ID, Isakovic AJ, Rakic ML, Thomas SA, Rakic LM. The kinetics of hypoxanthine transport across the perfused choroid plexus of the sheep. Brain Res 925: 169-175, 2002.
24. Rieger JM, Shah AR, Gidday JM. Ischemia-reperfusion injury of retinal endothelium by cyclooxygenase- and xanthine oxidase-derived superoxide. Exp Eye Res 74: 493-501, 2002.
25. Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther 19: 357-363, 2005.
26. Shayeghi M, Akerman R, Jarvis SM. Nucleobase transport in opossum kidney epithelial cells and Xenopus laevis oocytes: the characterisation, structure-activity relationship of uracil analogues and oocyte expression studies of sodium-dependent and -independent hypoxanthine uptake. Biochim Biophys Acta 1416: 109-118, 1999.
27. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79: 2-10, 1997.
28. Ward JL, Sherali A, Mo ZP, Tse CM. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275: 8375-8381, 2000.
29. Zhu Z, Hofmann PA, Buolamwini JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. Am J Physiol Heart Circ Physiol 292: H2921-H2926, 2007.